Trial Profile
A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Onconova Therapeutics
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 16 Oct 2019 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
- 16 Oct 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2020.